This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

3 Biotech Stocks Facing Crucial FDA Advisory Panels This Week

BOSTON ( TheStreet) -- Fans of FDA advisory panels have a riveting week of action ahead.

Starting Tuesday morning, outside experts invited by FDA will weigh the risks and benefits of three different drugs on three consecutive days. The recommendations that emerge from these FDA advisory panels will factor into the agency's approval decisions.

NPS Pharmaceuticals (NPSP) brings Gattex, a treatment for short bowel syndrome, in front of the Gastrointestinal Drugs Advisory Committee on Tuesday Oct. 16.

On Wednesday Oct. 17, the Endocrinologic and Metabolic Drugs Advisory Committee convenes for two days of hearings to review drugs aimed at helping patients with a rare genetic disorder that causes extremely high levels of cholesterol to accumulate in their blood.

The panel will review Aegerion Pharmaceuticals' (AEGR - Get Report) lomitapide on Wednesday followed on Thursday by mipomersen, a drug developed by Isis Pharmaceuticals (ISIS) and the Genzyme unit of Sanofi (SNY - Get Report).

I will be live-blogging all three FDA advisory panels with play-by-play and analysis in real time from the opening gavels all the way through the final votes. [You can sign up for email reminders for each panel below.]

NPS Pharmaceuticals:

Short bowel syndrome (SBS) is a chronic and disabling condition that strikes people, who for various reasons including Crohn's disease, have about 50% of their lower intestines surgically removed. A majority of patients can adapt to lead normal lives. A smaller group of SBS patients never recover full functionality of their lower intestines, and a result, must spend the rest of their lives attached to an intravenous parenteral nutrition bag that provides the liquid nutrients they need to survive.

Gattex is an analogue of GLP-2, a protein involved with intestinal growth and function. Administered via a shot under the skin, Gattex is designed to boost the ability of the intestine to absorb nutrients.

On Friday, NPS Pharma shares rose 19% to $10.86 due to a largely positive FDA review of Gattex released ahead of Tuesday's panel. The FDA appears to be concur with NPS Pharma that Gattex provides a clinically meaningful benefit for SBS patients. The agency also appears unconcerned about three cases of cancer reported in patients treated with Gattex.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AEGR $2.97 0.68%
ISIS $40.99 -0.92%
NPSP $45.97 0.02%
SNY $42.85 -1.77%
AAPL $95.03 -2.90%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs